Home » Authors » Aaron Lorenzo

Articles by Aaron Lorenzo

Sarbanes-Oxley Changes Proposed By Committee

Feb. 21, 2006

By Aaron Lorenzo

Onyx, Bayer Move Nexavar Into Yet Another Phase III

Feb. 17, 2006

By Aaron Lorenzo

Onyx, Bayer Move Nexavar Into Yet Another Phase III

Feb. 17, 2006

By Aaron Lorenzo

FDA Says Critical Path Key To Speeding Development

Feb. 16, 2006

By Aaron Lorenzo

FDA Says Critical Path Key To Speeding Development

Feb. 16, 2006

By Aaron Lorenzo

Inhibitex Outlining Plans For Veronate Commercialization

Feb. 15, 2006

By Aaron Lorenzo

Inhibitex Outlining Plans For Veronate Commercialization

Feb. 15, 2006

By Aaron Lorenzo

Novacea’s IPO Seeks $75M To Fund Late-Stage DN-101

Feb. 14, 2006

By Aaron Lorenzo

Greenwood Planning More Time Spent On Capitol Hill

Feb. 14, 2006

By Aaron Lorenzo

Greenwood Planning More Time Spent On Capitol Hill

Feb. 14, 2006

By Aaron Lorenzo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 22, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...